STOCK TITAN

Galapagos NV - $GLPG STOCK NEWS

Welcome to our dedicated page for Galapagos NV news (Ticker: $GLPG), a resource for investors and traders seeking the latest updates and insights on Galapagos NV stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Galapagos NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Galapagos NV's position in the market.

Rhea-AI Summary
BridGene Biosciences, a leader in small molecule drug discovery, announced a strategic collaboration and licensing agreement with Galapagos NV. The collaboration will focus on discovering novel small molecule drug candidates against oncology targets, with potential upfront and milestone payments of over $700 million. BridGene will use its chemoproteomics platform, IMTAC™, to advance molecules to clinical candidates, with Galapagos having exclusive rights to develop and commercialize them. The company is also eligible to receive tiered royalties on net sales of resulting products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary
Landmark Bio has signed a multi-year strategic manufacturing agreement with Galapagos NV to perform GMP manufacturing of clinical trial batches of Galapagos' CAR-T therapies in the Boston area. The agreement aims to implement Galapagos' decentralized CAR-T manufacturing model, which aims to address current limitations of CAR-T treatments. Landmark Bio's facility includes laboratory space, cleanrooms for cell therapies, and wraparound services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
Galapagos NV

Nasdaq:GLPG

GLPG Rankings

GLPG Stock Data

1.92B
44.54M
30.59%
2.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Malines Mechelen

About GLPG

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.